Abstract: The disclosed simulation environment, methods, and system support simultaneous design and analysis of assemblies with unified computer aided design (CAD) and finite element analysis (FEA). The system provides a simulation environment that is unified with the architecture of the assembly environment, which significantly reduces the amount of time it takes to set up structural simulations as compared to prior simulation tools. The system enables CAD designers to obtain accurate mechanical guidance such as strength and rigidity early and often in the design process, seeing the structural impact of CAD modifications at the sketch, part, and configuration level. Such guidance can be particularly helpful when CAD engineers are determining product fit and form, defining dimensions, and shaping the overall weight and volume of designs.

Abstract: A method for determining a region for safe placement of a device in a medical image includes receiving a medical image, detecting at least one anatomic landmark in the medical image using at least one deep convolutional neural network, determining the region for safe placement of the device based on the detected at least one anatomic region using a semantic network, and displaying the region for safe placement of a device on the medical image using a display.

Abstract: Stable and bioavailable extended-release formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyrid azine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

Abstract: Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

Abstract: A pharmaceutical composition contains the compound 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, and hydroxypropyl methyl cellulose (HPMC) having a viscosity of at least about 100 cP, wherein the composition does not contain any enzyme inhibitors.

Abstract: A pharmaceutical composition contains the compound 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, and hydroxypropyl methyl cellulose (HPMC) having a viscosity of at least about 100 cP, wherein the composition does not contain any enzyme inhibitors.